NASDAQ$AURA
Aura Biosciences Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Aura Biosciences reported its financial results for the fourth quarter and full year 2022, along with clinical development and operational highlights.
Aura Biosciences reported a net loss of $16.6 million for the fourth quarter of 2022. The company's cash and cash equivalents and marketable securities totaled $188.8 million as of December 31, 2022, which is expected to fund operations into 2025. The FDA granted Fast Track Designation for Belzupacap Sarotalocan for the treatment of Choroidal Metastasis.
- FDA granted Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the treatment of Choroidal Metastasis.
- Global Phase 3 Trial in Primary Choroidal Melanoma is on track to begin dosing in 1H 2023.
- Positive interim Phase 2 safety and efficacy data with suprachoroidal administration in early-stage choroidal melanoma was presented.
- Aura is enrolling a Phase 1 clinical trial of bel-sar for the treatment of non-muscle invasive bladder cancer (NMIBC).
Headline financials
Revenue & EPS history
Aura Biosciences · Revenue · Quarterly
$600K
Forward guidance
Aura believes its current cash and cash equivalents and marketable securities are sufficient to fund its operations into 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q4 2022
+1.3%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-7.0%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+26.0%
Q3 2021
Best reaction
-8.9%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.1% | -5.5% | -24.3% | |
| Q3 2025 | -0.7% | -2.9% | +17.4% | |
| Q2 2025 | +4.2% | -3.6% | -11.0% | |
| Q1 2025 | +1.9% | -0.5% | +6.8% | |
| Q4 2024 | -6.7% | -15.5% | -23.2% | |
| Q3 2024 | -7.3% | -15.0% | -24.2% | |
| Q1 2024 | -1.1% | +1.9% | +1.6% | |
| Q4 2023 | +2.9% | +1.7% | -5.4% | |
| Q3 2023 | +4.5% | +8.6% | +18.9% | |
| Q2 2023 | -8.9% | -8.8% | -16.4% | |
| Q1 2023 | +0.5% | +7.3% | +22.4% | |
| Q4 2022 | -1.0% | -1.0% | -15.6% | |
| Q3 2022 | +10.1% | +16.4% | +4.4% | |
| Q2 2022 | -0.5% | -2.6% | -19.0% | |
| Q1 2022 | +4.9% | +8.1% | -4.5% | |
| Q2 2021 | -1.5% | +8.7% | -21.4% | |
| Q4 2021 | -1.5% | +8.7% | -21.4% | |
| Q3 2021 | +26.0% | -1.1% | -10.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro